As the landscape of clinical research evolves, the Arizona Clinical Trials (ACT) Medical Park stands out as a leader in cutting-edge clinical research offering hope and innovation to patients facing MASH, as well as other chronic liver diseases and complex health conditions. We had the privilege of a private tour of this brand new state-of-the-art facility (their grand opening is September 19, 2024) with Dr. Naim Alkhouri, MD, FAASLD. ACT Medical Park highlights the progress in understanding and treatment of diseases that affect millions worldwide. For patients, it represents a critical step forward in the development of new therapies and medications. "We look forward to the transformative impact this facility will have on the lives of our patients and the broader healthcare landscape," Anita Kohli, CEO of Arizona Liver Health/Arizona Clinical Trials. By participating in these advanced clinical trials, patients have access to cutting-edge treatments and will contribute to the scientific discoveries that will shape the future of medicine. This unique blend of patient care and groundbreaking research ensures that the needs of those battling severe health conditions are met with the highest level of expertise and compassion, paving the way for better outcomes and a healthier tomorrow. Join us on this extensive tour and see every aspect of this incredible site. The video will give you an idea of the expanse of this 28,000 sq. ft. facility. American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, Global NASH Council, Global Liver Institute, European Liver Patients' Association - ELPA, LPI LIVER PATIENTS INTERNATIONAL, Arizona Liver Health, Nick Engelke, Mazen Noureddin, MD, MHSc, Echosens, Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim
Fatty Liver Alliance’s Post
More Relevant Posts
-
Drs. Mark Swain (Hepatologist), Kenneth Cusi/Kenny Cusi (Endocrinologist), Hsiao-Ming Jung (Primary Care) and Michael Betel (President and Founder of Fatty Liver Alliance) have a very engaging and informative discussion about referral and collaboration in this panel discussion from the NAFLD and NASH Primary Care Summit. A multi-disciplinary team is critical now more than ever, for patients who have MASLD and MASH. What are the Indications for referral to a specialist? What is the importance of interdisciplinary collaboration for optimal patient care? In this 'Referral and Collaboration Panel Discussion' experts emphasized the importance of a multi-disciplinary approach for managing MASLD and MASH patients. Dr. Mark Swain, President of Canadian Association for the Study of the Liver, and his colleagues highlighted the need for collaborative care with the patient at the center, recognizing the complexity of cases involving multiple comorbidities. They stressed the necessity of a team approach for a holistic and effective treatment strategy. Key points discussed include the need for primary care physicians to seek specialist assistance, the significance of interdisciplinary collaboration, and the importance of early diagnosis and treatment. The panel also touched on public health issues, the accessibility of treatments like the GLP-1 drug, and dietary challenges. A major takeaway for primary care providers is the use of FIB-4 for assessing liver disease risk, enabling a comprehensive and focused approach to patient care. Canadian Nurses Association, European Association for the Study of Obesity (EASO), EASL | The Home of Hepatology, American Association for the Study of Liver Diseases (AASLD), European Liver Patients' Association - ELPA, Global Liver Institute, Mark Donnison, EMBA, Philippe Garneau, Supriya Joshi, Cheryl Dale RN(EC) MScN AF-AASLD, The College of Family Physicians of Canada
Referral and Collaboration Panel MASLD and MASH - Primary Care
fattyliver.ca
To view or add a comment, sign in
-
Here is a MASLD (NAFLD/fatty liver disease) case study you have to watch! Professor Manal Abdelmalek, Hepatologist does a brilliant job presenting a case to her interdisciplinary colleagues. The discussion is incredible, as are the insights you will gain. Join Professor Kenneth Cusi, Endocrinologist (Kenny Cusi),and Dr. Joshua Juan, Primary Care Physician, as they discuss the case of a patient, Jorge, 55 years old who has multiple co-morbidities, including Type-2 Diabetes, Hypertension, obesity and Hyperlipidemia, who currently is feeling well. Dr. Alnoor Ramji, Hepatologist moderates and patient Kerry Sivia joins in for the Q & A. 1. Multidisciplinary Approach: The discussion emphasized the importance of a team approach involving primary care, endocrinology, hepatology, and nutrition to manage complex patient cases like Jorge's. It highlighted the need for comprehensive care beyond a single specialty to address the multifaceted aspects of metabolic syndrome and related complications. 2. Importance of Lifestyle Modifications and Patient Motivation: Despite medical interventions, the significance of lifestyle changes was underscored, alongside the challenge of motivating patients. Strategies to motivate patients, such as focusing on family, quality of life, and leveraging a patient's personal values and goals, were discussed as critical for managing chronic conditions effectively. 3. Role of Advanced Diagnostic and Monitoring Tools: The conversation highlighted the utility of diagnostic tools like FibroScan and the importance of monitoring biomarkers such as hemoglobin A1c, liver enzymes, and fibrosis scores. It stressed that these tools should guide clinical decisions, including when to escalate care to specialists or consider treatments like bariatric surgery or clinical trials for advanced therapies. 4. Complexity of Managing Comorbid Conditions: The case illustrated the complexity of managing comorbid conditions such as diabetes, obesity, and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), stressing the need for careful consideration of medication choices, potential side effects, and interactions. The discussion pointed out the challenges in balancing glucose control with the risk of weight gain and the potential for liver disease progression. 5. Preventative Care and Early Intervention: Finally, the importance of preventative care and early intervention was highlighted, emphasizing the need for regular monitoring, early referral to specialists when necessary, and consideration of patient history and risk factors for more severe conditions like cirrhosis and cardiovascular disease. Canadian Association for the Study of the Liver, Canadian Association of Hepatology Nurses, American Association for the Study of Liver Diseases (AASLD), European Liver Patients' Association - ELPA, EASL | The Home of Hepatology, MCI, Global Liver Institute, Canadian Family Physician, The The College of Family Physicians of Canada #masld
MASLD Case Study and Discussion: Primary Care Summit
fattyliver.ca
To view or add a comment, sign in
-
Global estimates of fatty liver disease (MASLD) exceed 38%, and this epidemic needs to be addressed with urgency. Jeffrey V. Lazarus et al., in this article, 'Turning the Tide on MASLD and MASH' (published in Hepatology), discuss an action plan to address this global epidemic. It won't be easy, but we need to work together and we need to start now. "Critically, implementing these actions will require a fundamental shift in the liver field from a narrow focus on hepatology to a more comprehensive approach that includes various stakeholders from different medical specializations, such as endocrinology, primary care, and cardiology, alongside public health experts, social scientists, policymakers and governments, pharmaceutical and device industries, patient advocates, and, most importantly, patients themselves." The top calls to action, based on their relevance to improving patient care and outcomes, include: * Collaboration between liver specialists and primary care * Addressing the needs of people with multiple morbidities * Incorporating fatty liver disease into existing NCD strategies and guidelines * Developing and implementing patient-centered models of care * Enhancing education and awareness * Promoting standardization of data collection * Implementing community-tailored models of care * Developing tools * Advocating for and establishing a global coalition * Engaging with health system decision-makers EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, American Association for the Study of Liver Diseases (AASLD), Canadian Association of Hepatology Nurses, European Liver Patients' Association - ELPA #liverhealth #masld #mash Alina M. Allen, Zobair Younossi, Aleksander Krag, Juan Pablo Arab, Quentin M. Anstee, Sven Francque, Naim Alkhouri, Mazen Noureddin, MD, MHSc, Christopher Kopka, Philip Newsome, Maru/Mary Rinella, Prof. Shira Zelber Sagi, Jörn M. Schattenberg, Diana Romero, Vincent Wong, marcelo silva Original paper: Hepatology 79(2):p 502-523, February 2024. | https://lnkd.in/g7pXzfF5
Turning the Tide on MASLD and MASH
fattyliver.ca
To view or add a comment, sign in
-
New Research from the National Kidney Foundation Spring Clinical Meetings: a new study compares chlorthalidone and hydrochlorothiazide in over 12,000 participants. Learn more by reading the National Kidney Foundation’s most recent bog: https://bit.ly/4bVsyDj #MedicalResearch #NKFofAZ #KidneyDisease #KidneyStrong #KidneyHealth #KidneyResearch
New Analysis on Hypertension Treatment Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings
kidney.org
To view or add a comment, sign in
-
Postgraduate Degree in Medical and Health Psychology, and bachelor’s degree in Psychology, with 15 years’ experience in psychological assessment, intervention in chronic illness, psychopathology and human resources.
Once again, research highlights the importance of psychoeducation in health care and adherence to medical treatments. A multidisciplinary intervention can make a difference in both short and long-term outcomes, and definitely can save lifes. Check out this important article from National Kidney Foundation
Patient-Centered Outcomes and Behavioral Health Expert | Healthcare Leader with Experience in Academic Medicine, Technology, and Consultation | Superpower: Translating Research to Improve Clinical Care and Quality
Before I started my second career in health technology, I was the psychologist for the kidney, liver, and lung transplant programs at a large academic health center. It was an honor to work with those patients and alongside the care teams that provided life-saving care for so many. That said, it was a complex system, sometimes difficult to navigate for patients and their families. One key lesson I learned from that experience is how important a role patient education and activation plays in those health journeys. But what happens earlier in the journey -- before end-stage organ disease? My colleagues at Phreesia recently partnered with the National Kidney Foundation to survey over 4k patients at risk for kidney disease. They found that patient-provider conversations and patient activation (the knowledge, skills, and confidence to self-manage their condition) were the two most significant predictors of a patient's engagement in kidney disease prevention behaviors. This finding has significant implications for how we optimize health for millions and prevent kidney disease from even starting. It's a quick read: https://lnkd.in/gkk9pJU8
Leveraging Patient Activation to Improve Kidney Health in High-Risk Patients
ajmc.com
To view or add a comment, sign in
-
Genetic studies are essential for the early and correct diagnosis of rare diseases.
#NARDS | The panel "Speeding Up Diagnostics with Innovative Solutions" has just started. This crucial discussion focuses on how cutting-edge approaches can revolutionize the diagnostic process for rare diseases, ultimately improving patient outcomes. Meet our esteemed panelists: 👉 Eric Klee, Associate Director for Research and Innovation, Center for Individualized Medicine, Mayo Clinic 👉Cheng-Kai Kao, Chief Medical Information Officer, University of Chicago Medicine 👉Krishna Tangella MD, MBA ✅, Full Clinical Professor of Pathology, University of Illinois & Medical Director of Laboratory, Sacred Heart Medical Center & CEO at DoveMed 👉Erin Conboy, MD, FACMG, Director, Undiagnosed Rare Disease Clinic at Indiana University School of Medicine 👉Tracy George, President, Innovation Business Unit & Chief Scientific Officer, ARUP Laboratories 👉 Joshua Wechsler, Medical Director, Eosinophilic Gastrointestinal Disorders Program, Lurie Children’s Hospital and a site-PI for Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Ultragenyx, Thrivewell Infusion, LLC, Novartis | Sanofi. #RareDiseases #HealthcareInnovation #OrphanDrugs #bamberghealth #RDSseries #rds #rareconditions #earlydiagnosis
To view or add a comment, sign in
-
Invizius has recently announced the latest update from its first-in-human trial for their novel priming solution, H-Guard, sharing that eight patients have been successfully treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF). To learn more about H-Guard and the successful trial, follow the link below to read the full article!
Invizius’s dialysis product H-Guard completes first in-human clinical study - Renal Interventions
renalinterventions.net
To view or add a comment, sign in
-
In collaboration with other funders, this is the difference supporters of Crohn's & Colitis UK make. This is IMPACT. This is WHY we do what we do. This is why investing in medical research is so vitally important. For Billie and for everyone living with IBD. https://lnkd.in/e4KBKfAu
'Incredibly positive': Bowel disease sufferers welcome scientific breakthrough
inews.co.uk
To view or add a comment, sign in
-
See this new interview with past About IBD Podcast guest and IBD specialist Dr Gaidos!
📰 "We are very fortunate that patients with IBD have so many treatment options, and our options are only increasing" Jill Gaidos Yale New Haven Hospital Yale New Haven Health Yale Department of Internal Medicine Crohn's & Colitis Foundation
Finding the Right IBD Therapy for Patients: A Q&A with Jill Gaidos, MD
medicine.yale.edu
To view or add a comment, sign in
-
🚨 Calling all researchers and pharmacists! We have two grant rounds opening today, Tuesday 4 June, for UK-based applicants. 1) Funding call for research into Alport syndrome In partnership with the Stoneygate Trust, we have established a UK hub dedicated to the study and treatment of Alport syndrome. The hub aims to accelerate research, transform early diagnosis, and develop specific treatments for the disease. We are looking for researchers who can transform Alport syndrome. For more information, click here: https://bit.ly/3PG99OQ 2) Pharmacy-led research and research into nephrotoxicity For the first time we are leading a collaborative drive to develop and enhance pharmacy-led research and pharmacy-related research in partnership with Pharmacy Research UK, The UK Kidney Association’s Renal Pharmacy Group, The Paediatric Medicines Research Unit, Alder Hey Children’s Hospital and the Thompson Family Trust. With a specific focus on nephrotoxicity, we want to help our understanding and prevent deterioration of kidney function due to toxic effects of medications and chemicals. In this funding call, we are looking for researchers with an interest in nephrotoxicity, and hospital and community-based pharmacists who want to undertake a renal research study. For more information, click here: https://bit.ly/3KbRTwW 📣 Share this with your contacts and help spread the word about our new and exciting grant rounds. #KidneyResearch #GrantRounds #Funding
To view or add a comment, sign in
9,615 followers
Business Development, Operations & Growth Executive ● Strategic Vision ● Marketing Leadership ● Operational Transformation ● Revenue Growth
2moThank you Michael Betel for the "walk about" of our new ACT Medical Park and ACT Phase 1 and ACT Imaging new facilities!